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Objectives: To examine HCV prevalence and management among people who inject drugs (PWID) attending
primary care and community-based health services at four European sites using baseline data from a multi-
centre feasibility study of a complex intervention (HepLink).
Methods: Primary care and community-based health services in Dublin, London, Bucharest and Seville were
recruited from the professional networks of the HepLink consortium. Patients were eligible to participate if aged
18 years, on opioid substitution treatment or at risk of HCV (i.e. injecting drug use, homeless or incarcerated),
and attended the service. Data on patient demographics and prior HCV management were collected on partici-
pants at baseline.
Results: Twenty-nine primary care and community-based health services and 530 patients were recruited.
Baseline data were collected on all participants. Participants’ mean age ranged from 35 (Bucharest) to 51 years
(London), with 71%–89% male. Prior lifetime HCV antibody testing ranged from 65% (Bucharest) to 95% (Dublin)
and HCV antibody positivity among those who had been tested ranged from 78% (Dublin) to 95% (Bucharest).
Prior lifetime HCV RNA testing among HCV antibody-positive participants ranged from 17% (Bucharest) to 84%
(London). Among HCV antibody- or RNA-positive participants, prior lifetime attendance at a hepatology/infec-
tious disease service ranged from 6% (London) to 50% (Dublin) and prior lifetime HCV treatment initiation from
3% (London) to 33% (Seville).
Conclusions: Baseline assessment of the HCV cascade of care among PWID attending primary care and
community-based health services at four European sites identified key aspects of the care cascade at each site
that need to be improved.
Introduction
Prevalence of HCV infection among people who inject drugs (PWID)
ranges from 5% to 90% in 29 European countries.1 Despite the high
prevalence of HCV among PWID, estimates of undiagnosed HCV
infection among PWID in Europe range from 24% to 76% and
among PWID diagnosed with chronic hepatitis C (CHC) just 1%–19%
have commenced HCV treatment.2 Consequently, modelling stud-
ies predict substantial increases in the burden of decompensated
cirrhosis among ageing HCV-infected PWID populations.3,4
Research has identified multiple barriers impeding PWID from
accessing HCV testing, follow-up evaluation and treatment, includ-
ing restrictions around HCV treatment eligibility; not being referred
for treatment; fear of HCV investigations (e.g. liver biopsy) and of
HCV treatment side-effects; competing priorities (such as drug use,
employment or family commitments); inconvenience of travelling
to testing locations and hospitals; anticipated stigma and discrim-
ination; perceptions of HCV as relatively benign; and being asymp-
tomatic.5–7
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To address the growing burden of HCV-related morbidity
among PWID and to achieve the WHO HCV targets for 2030,8 it is
essential that countries increase HCV prevention and screening
and the treatment of diagnosed individuals. As many PWID remain
unaware of their infection or are not accessing HCV care, new
strategies to reach such individuals are needed, including testing
strategies to increase the number diagnosed, and improved care
pathways to ensure those diagnosed as PWID are successfully
linked to HCV evaluation and treatment.
The design and evaluation of interventions that target and
simplify multiple aspects of the HCV cascade of care in the direct-
acting antiviral agent (DAA) treatment era is a research priority.9
Culturally appropriate and flexible models of care that meet the
specific needs and are adapted to the circumstances of PWID will
be essential to optimize HCV diagnosis and linkage to HCV evalu-
ation and treatment.10,11 Multidisciplinary, integrated models of
HCV care involving partnership between HCV specialists and com-
munity healthcare providers,12 and the continuing extension of
HCV care into community settings, will be an appropriate model of
HCV care adapted to the needs of PWID. Various integrated care
models have been described to enhance HCV assessment and
interferon-based treatment among PWID, including telemedicine
clinics between specialists and primary care providers,13 and on-
site HCV nursing and specialist support within opioid substitution
therapy (OST) clinics and community health centres.14,15
HepLink is an EU-funded project involving a consortium of five
institutions: University College Dublin (Ireland); Servicio Andaluz
De Salud (Spain); Spitalul Clinic de Boli Infectioase si Tropicale
‘Dr Victor Babes’ (Romania); University College London (UK); and
University of Bristol (UK). The aim of HepLink is to develop inte-
grated models of HCV care at participating sites in the consortium
(Dublin, Seville, Bucharest and London), tailored to health service
infrastructure and population health needs locally, with the aim of
improving engagement and retention along the HCV cascade of
care among PWID.16,17
The at-risk population and delivery of HCV services varies across
the countries participating in the HepLink consortium (Table 1).
While estimates of CHC in the general population are up to 30000
Table 1. National context – HCV and addiction treatment services in countries participating in the HepLink consortium
Characteristic Ireland Romania UK Spain
Chronic HCV infection
rate estimate
20000–3000021 48900018 21400019 47200020
HCV antibody prevalence
among PWID
62%–81%22–24 74%29 England 52%, Wales 53%,
Northern Ireland 23%,
Scotland 58%.19
60%–80%25
OST modalities Methadone, buprenor-
phine/naloxone.
Methadone (most com-
mon), buprenorphine,
buprenorphine/
naloxone.
Methadone, buprenorphine,
diamorphine.
Methadone, buprenorphine/
naloxone.
Where is OST available? Addiction treatment
centres, general practi-
ces, prisons.
Prevention, evaluation and
counselling centres, by
private providers and
NGOs, hospitals, prisons.
Primary care treatment centres,
specialist general practices,
prisons. Local Clinical
Commissioning Groups coord-
inate designation of services in
each local area.
Specialized outpatient drug
treatment centres, primary
care centres, mental health
centres, inpatient facilities,
prisons.
DAAs available to DAA therapies are the
standard of care and are
provided by specialist
hospital services.
Since early 2017, any pa-
tient with CHC is eligible
for DAA treatment
regardless of the stage
of liver fibrosis. Prior to
2017, CHC patients with
a FibroScan score of
>8.5 kPa were eligible for
DAA treatment.
Since September 2018,
CHC patients with fibrosis
stage Metavir F1 and
above are eligible for
DAA treatments.
To receive DAA therapy
without charge patients
must have health insur-
ance, identity card and
health card. At-risk
patients may not fit
these criteria and access
can be restricted as a
result.
Under NHS guidance, 2015, DAA
treatment was available for
CHC patients with genotype 1
and cirrhosis or any genotype
and decompensated cirrhosis.
Eligibility criteria have since
relaxed and DAAs are now
available to patients with all
genotypes and regardless of
stage of fibrosis.
Delivery of DAA treatment is con-
trolled by operational delivery
networks. Each patient is pre-
sented at a multidisciplinary
meeting and their eligibility for
treatment is determined. There
is a treatment quota for each
month.
Since June 2017, DAA thera-
pies are available to patients
with CHC regardless of stage
of fibrosis or clinical fea-
tures. DAA therapy was
previously restricted to
priority groups.
DAA therapy is provided by
the public sector as well as
by NGOs and private
organizations.
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in Ireland, estimates in Spain and Romania are approximately
472000 and 489000, respectively.18–21 Estimates of HCV antibody
prevalence among PWID range from 52% in England19 to up to
80% in Ireland and Spain.22–25 All four countries provide a number
of options for OST, although in Ireland methadone is the almost
universally prescribed formulation and buprenorphine/naloxone is
currently available on a limited named patient basis only.26 Access
to DAA therapies for HCV treatment has been expanding in recent
years in all four countries. Presently, in Ireland, England and Spain,
patients with CHC can access DAA treatments regardless of stage
of liver fibrosis. In Romania, DAA access was expanded in
September 2018 to all CHC patients starting from fibrosis stage
Metavir F1. However, the social circumstances of many PWID in
Romania mean they lack health insurance and the necessary
documents (identity card and health card) to access treatment.
This article examines baseline levels of HCV prevalence and HCV
management at the four different country sites in the HepLink con-
sortium (Dublin, Seville, Bucharest and London) through present-
ing baseline data collected prior to the introduction of the HepLink
model of care at each site. These data are important for highlight-
ing areas where improvement in the HCV care cascade is required
and will provide baseline data on HCV testing, referral and treat-
ment rates for the HepLink prospective, non-randomized pre/post-
intervention feasibility study.
Patients and methods
Ethics
The study was approved by the Mater Misericordiae University Hospital
Research Ethics Committee in Dublin (1/378/1722) and the Research Ethics
Committees of collaborating institutions in Bucharest (Victor Babes Clinical
Hospital for Infectious and Tropical Diseases, 3/06.01.2016), London (North
West – Haydock Research Ethics Committee, 17/NW/0417) and Seville
(Hospital Universitario de Valme, 0131-N-16). Regarding informed consent
and consenting capacity, all potential participants (GPs, patients) were
given written information on the study and the intervention being pro-
posed, and were asked to state in writing that they consented to participa-
tion and that non-participation would not compromise their usual care.
Participation in the study was on a voluntary basis. No inducements to par-
ticipation were offered. The study was conducted in accordance with the
Declaration of Helsinki (as revised in 2013) and with national and institu-
tional standards in each country.
Setting
The study was conducted in primary care and community-based health serv-
ices at four different country sites in the HepLink consortium: Dublin, Ireland;
Seville, Spain; Bucharest, Romania; and London, UK. Services participating in
the study at all four sites were OST-prescribing clinical services based in the
community and in primary care. In Bucharest, where OST coverage is lower,27
other community-based services that provide healthcare to PWID were also
recruited, including night shelters and prison services.
All participating services were recruited through the professional
networks/databases of the research consortium. In Dublin, OST-
prescribing general practices were recruited from the catchment area of
the Mater Misericordiae University Hospital infectious diseases clinic. In
Seville, large OST-prescribing primary care centres located in areas
where injecting drug use is prevalent were recruited. In London, OST-
prescribing primary care services with links to the pan-London Find &
Treat service were recruited. The Find & Treat service is a specialist out-
reach service provided by University College London Hospitals NHS Trust
to tackle TB among homeless people, drug or alcohol users, vulnerable
migrants and people who have been in prison. In Bucharest, the OST-
prescribing services and other community-based health services
recruited were those with whom the Infectious Diseases Department of
the Victor Babes Clinical Hospital for Infectious and Tropical Diseases
had pre-existing collaborations.
Study population
Participating patients were 18 years of age and on OST or at risk of
HCV. In Dublin, London and Seville, patients were eligible to participate if
they were aged at least 18 years, were receiving OST and attended the
service during the recruitment period. In Seville, patients who currently
or previously injected drugs but were not on OST were also included. In
Bucharest, patients were eligible to participate if they were aged at least
18 years, had any history of high-risk behaviour (including active or past
injecting drug use, homelessness or incarceration) and attended the
service during the recruitment period. In London, patients currently
receiving HCV treatment were excluded from the study. Patients inter-
ested in participating signed a consent form witnessed by the GP or re-
search team member.
Patients were recruited by healthcare professionals in the respective
services or by members of the research team. Methods of recruitment var-
ied from site to site and are outlined in Table 2. Participants recruited to the
HepLink study are a subset of the larger cohort of participants recruited to
the HepCheck study in London, Bucharest and Seville. In Dublin, participants
in the HepLink study are a separate cohort of participants from the
HepCheck participants.
Data collection
Prior to the implementation of the HepLink intervention at each site,
baseline data on patient demographics and prior HCV care were collected
from participants’ clinical records and/or from patient self-report via
researcher-administered questionnaires (Table 2), and included the follow-
ing variables:
• Prior HCV antibody test in lifetime
• HCV antibody status
• Prior HCV RNA test in lifetime
• HCV RNA status
• Referral to a specialist hepatology/infectious diseases service (for HCV)
in lifetime
• Attendance at a specialist hepatology/infectious diseases service in
lifetime
• Initiated HCV treatment in lifetime
• Completed HCV treatment in lifetime
• Achieved sustained virological response (SVR) in lifetime
In all sites except Seville, data were also collected on the following
variable:
• FibroScanned in lifetime
Past 12 month data on all of the above variables were also collected at
all sites. Baseline data collection was conducted between April 2016 and
December 2018.
Data analysis
Descriptive statistics were used to summarize participants’ characteristics
and study outcomes. Continuous variables were summarized using mean
with standard deviation or range and categorical variables using frequen-
cies or percentages. Analyses were conducted using Stata 13.1 (College
Station, TX, USA).
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Results
Across the four different country sites, 29 primary care and
community-based health services participated: Dublin (n=14);
London (n=2); Seville (n=4); and Bucharest (n=9). A total of 530
patients were recruited (Dublin n=135; London n=35; Seville
n=130; Bucharest n=230) and baseline data were collected on all
participants. The mean age of participants ranged from 35 years
(Bucharest) to 51 years (London) (Table 3). Male participants
(n=435; 82.1%) were predominantly represented.
Screening for hepatitis C
When considering HCV antibody testing across the four different
country sites at baseline, diversity was observed in lifetime HCV
testing rates, with rates ranging from 65.2% in Bucharest,
86.2% in Seville, 94.3% in London and 94.8% in Dublin (Table 3).
A positive HCV antibody status was observed in 78.1% (Dublin)
to 95.3% (Bucharest) of those that had been tested. When con-
sidering screening conducted in the 12 months previous to the
study, 68/530 (12.8%) participants across the four sites had
Table 3. Participant demographics and lifetime hepatitis C screening and infection status
Variable
Dublin London Bucharest Seville Total
(N=135) (N=35) (N=230) (N=130) (N=530)
Gender
male 71.9% (97) 71.4% (25) 85.7% (197) 89.2% (116) 82.1% (435)
female 28.1% (38) 28.6% (10) 14.3% (33) 10.8% (14) 17.9% (95)
Age, years, mean (SD) 42.8 (7.6) 51.3 (8.8) 35.2 (7.9) 50.0 (6.4) –
HCV antibody tested 94.8% (128) 94.3% (33) 65.2% (150) 86.2% (112) 79.8% (423)
HCV antibody positive/tested 78.1% (100) 93.9% (31) 95.3% (143) 87.5% (98) 87.9% (372)
Table 2. Local context – characteristics of participating sites
Characteristic Dublin Bucharest London Seville
Participating services 14 OST-prescribing general
practices in North Dublin.
(7 Level 1 OST-prescribing
practices,
7 Level 2
OST-prescribing
practices.a)
9 services in Bucharest:
3 centres for OST, 3 night
shelters, 2 prisons, 1 other
healthcare facility.
2 OST-prescribing primary
care services commissioned
to test for HCV and refer for
treatment in London (North
and South London drug
services and GP shared care
patients.)
4 OST-prescribing primary
care centres in health
districts north and south
of Seville.
Recruited patients 135 230 35 130
eligibility criteria Aged18 years.
On OST.
Attend the service.
Aged18 years.
High-risk behaviour i.e. ac-
tive or past injecting drug
use, homeless, prisoners.
Attend the service.
Aged18 years.
On OST.
Not currently on HCV
treatment.
Attend the service.
Aged18 years.
On OST or history of injecting
drug use.
Attend the service.
other comments A standardized non-prob-
ability sampling frame-
work was used to recruit
approximately 10 con-
secutively presenting,
eligible patients from
each practice.16
Participants were recruited
following invitation to
screening at the relevant
site.
All patients who met the eligi-
bility criteria and attended
the service during the
recruitment period were
invited to participate.
All patients who met the eligi-
bility criteria and attended
the service during the
recruitment period were
invited to participate.
Data collection Manual review of patients’
medical records.
Patient self-report via re-
searcher-administered
questionnaires, with use
of medical records where
available.
Patient self-report via re-
searcher-administered
questionnaires,
supplemented with
case note review.
Patient self-report via re-
searcher-administered
questionnaires, with use
of medical records.
Date baseline data
collected
2016–17 2016–18 2017–18 2017–18
aAt Level 1 practices, methadone is prescribed to fewer than 15 patients. At Level 2 practices methadone is prescribed to 15 or more patients and GPs
are subject to more regular audit and training. ‘Level two’ GPs can initiate patients on OST whereas ‘level one’ GPs can only treat patients already sta-
bilized on OST.
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been tested and of these 57/68 (83.8%) were HCV antibody
positive.
Subsequent care of HCV antibody-positive patients
Table 4 presents the cascade of care among HCV antibody-positive
participants at the four sites. Across the sites, lifetime RNA testing
among HCV antibody-positive participants ranged from 16.8%
(Bucharest) to 83.9% (London), with rates of RNA positivity among
those who had been RNA tested ranging from 33.3% (Bucharest)
to 95.6% (Seville). When considering RNA testing in the 12 months
prior to the study across the four sites, testing was performed in far
fewer of the HCV antibody-positive participants, with rates of 0.7%
(Bucharest) to 12.9% (London) observed; 56.3% (9/16) of those
who had been RNA tested in the previous 12 months across the
four sites were RNA positive.
Of the 373 participants known to be HCV antibody or RNA posi-
tive across the four sites, 197 (52.8%) had been referred to a hepa-
tology or infectious disease specialist during their lifetime, with the
highest referral rate in Dublin (69.3%). In the 12 months before the
study, 44/373 (11.8%) antibody- or RNA-positive participants had
been referred. Lifetime attendance at a hepatology/infectious dis-
eases service among HCV antibody- or RNA-positive participants
showed considerable differences between the sites, with 50.5% of
HCV antibody- or RNA-positive participants ever attending in
Dublin, 45.9% attending in Seville, 41.3% attending in Bucharest
and 6.5% attending in London. Attendance at hepatology/infec-
tious diseases services in the 12 months before the study ranged
from 0% (London) to 25.7% (Dublin) of HCV antibody- or RNA-
positive participants, with 51/373 (13.7%) antibody- or RNA-
positive participants across the four sites attending in the past
year. A FibroScan had ever been carried out in 27 (9.8%) of the 275
HCV antibody- or RNA-positive participants in Dublin, London and
Bucharest.
Across the four sites, HCV treatment had ever been initiated in
3.2% (London) to 32.7% (Seville) of HCV antibody- or RNA-positive
participants. Among the 373 antibody- or RNA-positive partici-
pants across the four sites, a total of 68 (18.2%) had ever initiated
HCV treatment, 51 (13.7%) had ever completed treatment and 40
(10.7%) had ever attained SVR (Table 4).
Discussion
Key findings
We examined HCV prevalence and HCV management among
PWID attending primary care and community-based health serv-
ices at four European sites (Dublin, London, Bucharest and Seville)
using baseline data from a multicentre feasibility study of a com-
plex intervention. Services participating in the study were OST-
prescribing clinical services based in the community and in primary
care, and in Bucharest, where OST coverage is lower,27 other
community-based services which provide healthcare to PWID
were also recruited, including night shelters and prisons. The
cohorts recruited at the four different sites differ in terms of mean
age and the proportion of male participants. Although cohorts are
not comparable across the four sites, they provide important data
on the HCV cascade of care at each site and the aspects of the care
cascade that need to be improved.
Baseline rates of HCV screening were high (>90%) in Dublin and
London and less than optimal in Seville (86%). The lowest screening
rate (65%) was observed in Bucharest, where the study recruited
from services caring for more marginalized PWID (e.g. street home-
less and prisoners). The rate of RNA testing among HCV antibody-
positive patients was high in London (84%). In Dublin and Seville, a
substantial minority of HCV antibody-positive patients had never
been RNA tested (43% Dublin and 31% Seville). Bucharest had the
lowest RNA testing rate (17%) among HCV antibody-positive
patients, as many PWID in Romania lack health insurance and the
necessary documents (identity card and health card) to receive spe-
cialist HCV evaluation and treatment. At all four sites, substantial pro-
portions of HCV antibody-positive patients (31%–55%) had never
been referred to hepatology or infectious diseases services. Among
those ever referred, lifetime attendance was high in Bucharest (91%)
and Seville (100%). However, lifetime attendance among those ever
referred was suboptimal in Dublin (73%) and very low (12%) in
London. In addition, attendance rates for the 12 months before the
study among those ever referred was low at all four sites (0%–
25.7%). Treatment initiation rates among HCV antibody-positive
patients were generally low across the four sites (3%–33%). This
may be explained in part by the suboptimal referral to secondary
care at all sites, and the poor attendance in London amongst those
Table 4. Management of anti-HCV antibody-positive patients
Variable
Dublin London Bucharest Seville Total
(N=100) (N=31) (N=143) (N=98) (N=372)
HCV RNA tested 57.0% (57) 83.9% (26) 16.8% (24) 69.4% (68) 47.0% (175)
HCV RNA positive/RNA tested 61.4% (35) 92.3% (24) 33.3% (8) 95.6% (65) 75.4% (132)
N=101a N=31 N=143 N=98 N=373
Referred to hepatology/infectious disease service 69.3% (70) 54.8% (17) 45.5% (65) 45.9% (45) 52.8% (197)
Attended hepatology/infectious disease service 50.5% (51) 6.5% (2) 41.3% (59) 45.9% (45) 42.1% (157)
FibroScan 16.8% (17) 0% (0) 7.0% (10) NA 9.8% (27)
HCV treatment initiated 19.8% (20) 3.2% (1) 10.5% (15) 32.7% (32) 18.2% (68)
HCV treatment completed 13.9% (14) 3.2% (1) 7.7% (11) 25.5% (25) 13.7% (51)
SVR attained 13.9% (14) 3.2% (1) 2.8% (4) 21.4% (21) 10.7% (40)
NA, not applicable (Seville did not collect data on these variables).
aThis figure includes one patient who was HCV antibody negative but RNA positive.
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referred. However, among HCV antibody-positive patients who had
ever attended secondary care, treatment initiation rates were low in
both Bucharest (25.4%) and Dublin (39.2%). The treatment initiation
rate among HCV antibody-positive patients who had ever attended
secondary care in Seville was high (71.1%). Restrictions regarding
DAA treatment eligibility in Romania and Ireland at the time of data
collection may be regarded as a contributory factor to the low treat-
ment rates. These data highlight areas in which the HCV cascade of
care needs to be improved (Figure 1).
Comparison with existing literature
This study observed high rates of HCV antibody positivity among
those who had been tested across the four sites (78%–95%). The pro-
portion testing HCV antibody-positive in Dublin (78%) is similar to pre-
viously published estimates.22–24 The percentage of patients testing
HCV antibody-positive in London (94%) is considerably higher than
reported rates for PWID in England (52%)19 and London specifically
(55%).28 In Bucharest, the proportion testing antibody positive (95%)
is higher than that reported for Romania (74%) in the review of anti-
HCV prevalence among PWID by Nelson et al.29 In Seville, 88% of
those who had been tested were HCV antibody positive, which is
slightly higher than published estimates of 60%–80% among PWID
in Spain.25 The higher infection rates observed in our study are likely
due to participating services being OST-prescribing services and the
relatively older age of our cohorts; thus, participants have likely had a
longer period of time exposed to risk of HCV infection.
The percentages testing HCV RNA positive varied across the
sites from 33% of those RNA tested in Bucharest, to 61% in Dublin,
92% in London and 96% in Seville. The low RNA-positive rate in
Bucharest is partly explained by the limitations of patient self-re-
port, where many patients did not know their RNA test results. A re-
cent systematic review of HCV RNA prevalence among people with
recent injecting drug use estimated rates of RNA positivity of 23%
in England, 53% in Spain, 56% in Ireland and 63% in Romania.30
The higher chronic infection rates in the London and Seville cohorts
in our study may be due to a potential bias in cohort selection. It is
possible that services focused more on recruiting patients who
were known to be chronically infected but disengaged from care,
given that the study involved a linkage to care intervention.
Only 18% of HCV antibody-positive patients across the four sites
had ever commenced HCV treatment, which is similar to previous
reports.2 A recent systematic review and meta-analysis examining
regional differences in HCV treatment rates among CHC patients
(not restricted to PWID) found a treatment rate of 34% for the
European region.31
Similar to our findings, a study of HCV care milestones achieved
by HCV antibody-positive patients in three community-based pri-
mary care clinics in the Bronx, New York, identified multiple deficien-
cies in the HCV cascade of care.32 More than 20% of HCV antibody-
positive patients identified through risk-based and birth cohort
screening in their study did not receive confirmatory viral load test-
ing to determine chronic infection. Just 43% of the antibody-positive
patients were referred for specialist HCV care, and less than 4% initi-
ated HCV treatment.32 Likewise, a study examining the HCV cascade
of care among PWID with CHC in Vancouver, Canada, found that the
step in the cascade of care from ever attending an HCV specialist to
commencing HCV treatment involves substantial attrition among
PWID. In their study, while a high proportion of PWID with CHC had
ever seen an HCV specialist (87%), just 10% had ever initiated HCV
treatment. Patient as well as system factors were responsible for
the low treatment rate, as 70% of PWID who had been offered
treatment had declined to take it, with concerns about side effects
and being asymptomatic being the most common explanations
given for refusing treatment.7
Strengths and limitations
This study was conducted in countries with autonomous service in-
frastructure and differing populations. Participating services were
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Figure 1. Cascade of care for HCV antibody-positive PWID attending primary care and community-based services in four European cities. AVT, anti-
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recruited through the professional networks/databases of the con-
sortium members and therefore are not a random sample of pri-
mary care and community-based health services caring for PWID
at each site. In Dublin, London and Seville, cohorts were recruited
from OST-prescribing services and therefore the findings may not
be generalizable to PWID who are not engaged in addiction
treatment. In addition, we did not collect data on the number and
characteristics of patients who refused to participate in the study.
The methodology of collecting data varied between sites, with
Seville, London and Bucharest using patient self-report via
researcher-administered questionnaires, augmented by medical
record or case note review where available, and Dublin using med-
ical record review only. It is not clear what impact the difference in
data sources had on study outcome measures.
However, this study provides a baseline assessment of the HCV
cascade of care among PWID attending OST-prescribing primary
care services and other community-based health services at
four European sites, which is crucial for evaluating where improve-
ments to the care cascade are needed. The study provides a bench-
mark for testing, referral and treatment levels so that increases in
these can be targeted through the introduction of new interventions.
Implications for practice, policy and future research
Baseline data presented here highlight the need for better linkage
to HCV evaluation and treatment in all sites and increased screen-
ing in Bucharest and Seville. The HepLink model of care has since
been introduced at the four sites and aims to integrate primary
and secondary care services to facilitate linkage to HCV evaluation
and treatment among PWID. The key components of the HepLink
model are: (i) outreach of an HCV-trained nurse into primary care
and community-based services to provide clinical support and
facilitate referrals to hepatology and infectious diseases services;
(ii) patient and health professional education on HCV and develop-
ments in its diagnosis and treatment; and (iii) community-based
evaluation of HCV disease (including FibroScan to stage liver
fibrosis). Through the evaluation of post-intervention data, it will
be possible to discern the feasibility and acceptability of these
interventions at the four different country sites and identify where
further refinement is needed. Cross-sectional analyses of the data
will provide insights into the uptake of the interventions, while lon-
gitudinal data will provide information on the potential impact of
the interventions over time, including retention of participants
through the HCV cascade of care.33
The HepLink model of care has the potential to improve access
to HCV care and provide quality healthcare to marginalized popu-
lations who might otherwise remain undiagnosed and untreated.
Evaluation of post-intervention data will enhance the scientific
understanding of interventions that contribute to health and social
gain locally and internationally. If successful, the HepLink model
could be easily implemented in other sites and could inform
national and European policy and service development.
Conclusions
Baseline data on HCV prevalence and HCV management among
PWID attending primary care and community-based health serv-
ices at four European sites highlight the need for better linkage to
HCV evaluation and treatment in all sites and increased testing in
Bucharest and Seville. It is paramount that effective interventional
strategies are developed and implemented in primary and com-
munity care settings in order to facilitate HCV treatment among
PWID and to achieve the WHO goal of eliminating the virus as a
major public health threat by 2030. Characterization of the HCV
cascade of care among PWID is crucial to developing appropriate
strategies and monitoring their impact.34
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